CLIMATE-FRIENDLY, material saving, affordable, customisable and ultra-thin – Romaco Siebler’s Push Pack manufacturing technology for push-through four-sided sealed strips heralds in a new era in primary packaging for solid pharmaceutical products. The leading global supplier of strip packaging machines got together with Huhtamaki, the Finnish film and foil specialist, to develop its Push Pack product family. Romaco Siebler is currently the only machinery supplier in the market with the capability to process the new, ultra-thin, PVC-free Huhtamaki foils into safe and absolutely tight pharmaceutical packs.
The push-through strip packs in the Push Pack product family are Romaco and Huhtamaki’s alternative to the established blister packaging forms presently available in the market. Push Packs provide equivalent barrier properties to blisters and are opened in the same way: you simply press the tablet out of the Push Pack with your thumb just as you would normally do with a blister. Push Packs are also similar in appearance to conventional blister packs: for example, the standard Push Pack version can be combined with transparent foil for an unobstructed view of the contents.
Up to 60 per cent cost saving compared to aluminium-aluminium blisters
Since Push Packs are sealed all round with two foils, far thinner aluminium barrier layers can be realised than with cold-formed blisters, namely between 9 and 25 μm depending on the primary packaging’s barrier specifications. With aluminium-aluminium blisters, on the other hand, the fact that the aluminium is deep-drawn means that very thick foil is inevitable. That is why a cold-formed aluminium-aluminium blister weighs more than twice as much as a high-barrier Push Pack produced on a Siebler strip packaging machine.
This markedly lower material consumption goes hand in hand with significant cost economies: a potential saving of up to 60 per cent is possible compared to standard aluminium-aluminium blisters. “Push Packs not only help pharmaceutical companies reduce their carbon footprint; they also let them produce much cheaper," explains Rolf Izsak, the Product Manager responsible for Push Pack development at Romaco Pharmatechnik GmbH.
The standard and high-barrier Push Pack versions are manufactured from a five-layer, laminated PE or Surlyn, aluminium and PET foil from Huhtamaki. The foil’s push-through function is achieved by perforating the outer PET layer. In the standard version, Push Packs have an aluminium barrier layer just 9 or 12 μm thick. High-barrier Push Packs, which have to meet very high light, air and moisture tightness requirements, are made using 25 μm aluminium foil. Thanks to the tear-resistant PET film, children find it extremely difficult to open Push Packs whereas elderly people can press the tablets out without any problem. And since the relatively small cavities in the Push Packs also mean smaller air pockets, the medicines have a longer shelf life. What’s more, unlike many blister forming foils, Push Packs contain zero PVC – a material considered harmful to health and the environment alike.
The world’s first recyclable unit dose packaging for pharmaceutical solids
Continue reading your story on the app
Continue reading your story in the magazine
We might need to redefine our approach to drug discovery and approval to be prepared for the future
Hitesh Windlass, MD,Windlas Biotech gives an overview of the changes bought by COVID-19 pandemic in the pharma industry, his organisation’s plans for future growth and more, in an interview with Lakshmpriya Nair
We help our customers create future-ready pharma manufacturing and biotech facilities
Sanjay Sudhakaran, VP, Digital Energy, Schneider Electric India expands on the value proposition of digital energy systems for the pharma sector, giving some examples of how companies achieved RoI on this investment, in an interaction with Viveka Roychowdhury
Virtual clinical trials would have a tremendous advantage in expanding the reach of clinical trials
Suneela Thatte, VP and Head - R&D Solutions India, IQVIA speaks on the challenges faced by CROs due to the pandemic, the subsequent learnings in clinical research/trials, emerging trends in this arena and more, in an interaction with Viveka Roychowdhury
Waters Corporation appoints Pearl S Huang to Board of Directors
She has significant scientific expertise in the discovery of biologics, small molecule and nucleic acid-based therapies, as well as in drug discovery and the development of clinical trials
Fighting counterfeiting requires a long-term battle and we need to start somewhere
Globally, incidents of fake, counterfeit pharma products are on the rise and recent cyber attacks on some pharma companies involved in the development of COVID-19 vaccines are raising further alarm. Nakul Pasricha, President, Authentication Solution Providers’ Association (ASPA) talks about the need for a phygital approach to secure supply chain integrity and facilitate easy identification of genuine COVID-19 vaccines, with Usha Sharma
FDI in brownfield pharma projects - Critical analysis
Arvind Sharma, Partner, Shardul Amarchand Mangaldas & Co informs that the extant regulatory regime for FDI in brownfield projects follows a balanced approach as it safeguards supplies for domestic consumption and ensures foreign investments as well as technological advancement for the pharma sector
Effective effluent management: Key to tackle AMR
Dr Jyoti Joshi, Head-South Asia,The Center for Disease Dynamics, Economics & Policy (CDDEP); Adjunct Professor,Amity Institute of Public Health emphasises that the government and the pharma industry need to establish strategic partnerships to address the issue of growing AMR due to pharma plant effluents
CIMS Medica organises Business Excellence Awards 2020
The award ceremony was held at the The Leela Palace Hotel, New Delhi to honour companies who contributed to the growth and development of the healthcare and pharma industry
BLUEPRINT FOR PROGRESS
Experts and veterans examine and explore strategies for India Pharma Inc to implement the lessons learnt from the COVID-19 pandemic as we enter a new year and a new decade
Reverse Brain Drain: Accelerated By Covid-19
Ankit Goyal, Healthcare and Lifesciences Leader India, Heidrick & Struggles finds that leadership hiring is attracting ‘returnee Indians’ in healthcare companies due to growing opportunities in India, and more recently, the impact of the pandemic